Please select the eligibility criteria that correspond to the clinical trial below.
Title: COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
Brief Summary: General objective:

To assess the effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment + psychoeducation) in patients with first episodes psychosis (FEP) cannabis users.

Design A multicenter single-blind randomized study with 1 year of follow-up. The effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment + psychoeducation) in patients with first episodes psychosis (FEP) cannabis users will be assessed.

Patients will be randomly assigned to one of two treatments:

1. Experimental group (N=50): Cognitive-behavioral treatment specific for cannabis abuse + pharmacological treatment
2. Control group (N=50): standard treatment: psychoeducation + pharmacological treatment


Options:
A: Inclusion Criteria:

* Enrolled patient at Community Psychiatric Clinic (CPC), a large mental health center in urban Seattle, Washington;
* Between 18 and 65 years of age;
* Diagnosis of of methamphetamine, amphetamine(illegal), or cocaine dependence or abuse;
* CPC medical record diagnosis of schizophrenia, schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder
* Stimulant drug use one month before enrollment;
* Ability to understand written and spoken English;
* CPC clinical case manager must affirm the potential participant's ability to provide informed consent and clinical appropriateness (i.e., safety/severity of mental/substance/ physical health) to participate in the study.

Exclusion Criteria:

* Any medical/psychiatric condition, or severity of that condition, that, in the opinion of Dr. Ries, the PI, would compromise safe study participation
* Chart defined organic brain disorder or dementia;
* Current participation in a methadone maintenance program;
* Any other circumstances that in the PI's opinion precludes safe study participation.
B: Inclusion Criteria:

1. SCID Diagnosis of a psychotic disorder (schizophrenia, schizoaffective disorder, or psychosis not otherwise specified) or a major affective disorder (major depression, bipolar disorder, or depressive disorder not otherwise specified, provided in the latter case that criteria have been met for a major depressive episode).
2. SCID diagnosis of alcohol abuse or dependence which is active within the past 1 month (i.e., not in early or sustained full remission).
3. Two or more days of heavy drinking (5 or more drinks for per occasion for a man, 4 or more drinks per occasion for a woman) in the 30 days prior to screening.
4. Willingness to participate in specialized 12-step programs.
5. Ability to provide informed consent.
6. Ability to read, speak, and understand English at least the 5th grade level.
7. Ability to provide at least one contact person to assist in tracking for follow-up assessment.

Exclusion Criteria:

1. Current attendance of any 12-step program (two or more 12-step meetings in the past month).
2. Unstable psychiatric illness, defined by psychiatric hospitalization in the past 1 month; more than 3 hospitalizations in the past year; or psychosis or mania which would render the individual incapable of informed consent.
3. Active suicidality (any clinically significant suicide attempts in the past 3 months or any current suicidal intent or definite plan).
4. Current homicidal ideation aimed at a specific person or persons.
5. Medical illness which is severe enough to compromise participation in the study.
6. Mental retardation, dementia, or other cognitive impairment of sufficient severely to render the individual incapable of informed consent or incapable of comprehending and participating in the TSF therapy or 12-step meetings.
7. Expectation of being out of town or in jail for more than 21 days during the treatment period.
8. Expectation of participation in any other formal addiction treatment during the study period (not including TAU, 12-step or other mutual support groups).
9. Current engagement in behavioral health treatment (including case management) at another facility.
10. Current engagement in non-TAU treatment at UNMPC, such as psychotherapy, intensive outpatient treatment, or MET.
C: Inclusion Criteria:

1. - Having a first psychotic episode. DSM-IV-TR diagnosis of a psychotic disorder (i.e. schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, bipolar disorder, atypical psychosis, brief psychotic disorder, or major depressive disorder with psychotic symptoms).
2. - Being a regular cannabis user according DSM-IV
3. -Being in remission from the first psychotic episode (not exceeding 5 years).

Exclusion Criteria:

1. Presenting organic brain pathology.
2. Presenting mental retardation according to DSM-IV criteria.
D: Inclusion Criteria:

* adults (age 18+)
* both sexes
* associated with one of the two participating community mental health centres
* diagnosed following the ICD-10 criteria of schizophrenia or bipolar disorder
* able to speak and understand Danish
* giving informed consent verbally and in writing

Exclusion Criteria:

* have a guardian or a forensic psychiatric arrangement
* comorbidity with the ICD-10 criteria of the diagnoses of dementia or mental retardation
* a large-scale substance abuse - if later on the abuse is under control inclusion in the trial will be possible
* a current home of supported housing - since the treatment as usual given to this group of patients is significant different from patients living independently
* a current involvement in a psycho-educational course - patients are eligible for participation in the trial after the psycho-educational course has ended if they meet the inclusion criteria at this point
* not given informed consent.

Answer: C